|Articles|January 28, 2015

Merck and Novo Nordisk Join TransCelerate

TransCelerate BioPharma Inc. today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization.

TransCelerate BioPharma announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization, bringing the total number of members to 23. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors.   Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content